Revlimid® (lenalidomide): New important advice regarding viral reactivation


User Rating: 4 / 5

Star ActiveStar ActiveStar ActiveStar ActiveStar Inactive

Date: 13 April 2017



Cases of viral reactivation have been reported following treatment with lenalidomide, particularly in patients previously infected with the varicella zoster or hepatitis B viruses (HBV). Some cases of HBV reactivation progressed to acute hepatic failure and resulted in death. As such, hepatitis B virus status should be established before initiating treatment with lenalidomide and a physician with expertise in the treatment of hepatitis B should be consulted for patients who test positive for HBV infection. For previously infected patients, they should be closely monitored for signs and symptoms of viral reactivation, including active HBV infection, throughout therapy. Please refer to the Direct Healthcare Professional Communication (DHPC) issued by Celgene Sdn. Bhd. in agreement with NPRA for further information.